Glass Pharms has today announced a new supply deal set to see a new line of affordable, entirely UK-produced products enter the market.
Under the collaboration, Glass Pharms will supply high-quality cannabis flower for use in Mamedica-branded, clinician-prescribed products, reinforcing the value of a fully domestic supply chain for CBPMs (Cannabis-Based Products for Medicinal Use).
The second in our series of guest episodes features a discussion between CEO of Releaf, Tim Kirby, and James Duckenfield,
Since the UK legalisation of CBPMs in 2018, the sector has faced slow adoption due to ineffective patient outreach, inconsistent supply chains and variable quality control from other providers.
Allowing medical cannabis to be prescribed on the NHS for chronic pain could save the state healthcare provider almost £4 billion annually, according to a new research study.
A multi-year medical cannabis research project in Scotland has secured £350k in funding to standardise cannabis plants for pharmaceutical use, spearheaded by the James Hutton Institute.
UK-based medical cannabis cultivator Glass Pharms has announced the launch of a new range of own-branded ‘cannabis-based products for medicinal
Medical cannabis cultivator Glass Pharms has officially delivered its first crop to the first UK-based clinic, marking the first time
UK medical cannabis cultivator Glass Pharms has officially completed the construction of its 2.4 hectare ‘state-of-the-art’ carbon negative cultivation facility
November 01 this year marks five years since the UK government legalised cannabis-based products for medicinal use in 2018 and
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
